Market revenue in 2023 | USD 49.9 million |
Market revenue in 2030 | USD 66.1 million |
Growth rate | 4.1% (CAGR from 2023 to 2030) |
Largest segment | Anti-infective |
Fastest growing segment | Chemotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti-Infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, Specialty Pharmaceuticals |
Key market players worldwide | CVS Group PLC, Walgreens Boots Alliance Inc, UnitedHealth Group Inc, BrightSpring Health Services Inc, Fresenius Medical Care AG, ICU Medical Inc, B. Braun Medical, Baxter International Inc, BD, Smiths Group PLC, Terumo Corp, Caesarea Medical Electronics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to home infusion therapy market will help companies and investors design strategic landscapes.
Anti-infective was the largest segment with a revenue share of 26.85% in 2023. Horizon Databook has segmented the Egypt home infusion therapy market based on anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, specialty pharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
According to World Bank Group, the country’s population aged 65 & above accounted for nearly 5.2% of the total population in 2017 and around 5.3% in 2019. Rise in geriatric population is anticipated to increase the demand for long-term and home care services, thereby fueling the market growth. The Central Administration for Pharmaceutical Affairs (CAPA) regulates the medical device industry in the country.
In 2018, CAPA expanded its medical device oversight regulations to include all Class I sterile, Class IIa, Class IIb, and Class III medical devices under its oversight. These regulatory changes are anticipated to drastically change the medical device registration process in the country, thereby increasing regulatory scrutiny of medical devices and IV solutions, including infusion systems. Reimbursement policies pertaining to medical devices are not well-established, which may impede market development in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Egypt home infusion therapy market , including forecasts for subscribers. This country databook contains high-level insights into Egypt home infusion therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account